EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 157 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Skin cancer death rates in men risen dramatically in the last... July 14, 2022 ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ March 8, 2019 Woman Dances Through Chemo Sessions, Emphasizes Importances of Being ‘Joyful’ March 4, 2021 Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers November 15, 2023 Load more HOT NEWS Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... Man Gets His First Haircut In 15 Years To Join The... Empoderar a las personas con cáncer: preguntas y respuestas con la...
